These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30649385)

  • 1. The Genomic Landscape of Mucinous Breast Cancer.
    Pareja F; Lee JY; Brown DN; Piscuoglio S; Gularte-Mérida R; Selenica P; Da Cruz Paula A; Arunachalam S; Kumar R; Geyer FC; Silveira C; da Silva EM; Li A; Marchiò C; Ng CKY; Mariani O; Fuhrmann L; Wen HY; Norton L; Vincent-Salomon A; Brogi E; Reis-Filho JS; Weigelt B
    J Natl Cancer Inst; 2019 Jul; 111(7):737-741. PubMed ID: 30649385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
    Pareja F; Selenica P; Brown DN; Sebastiao APM; da Silva EM; Da Cruz Paula A; Del A; Fu L; Weigelt B; Brogi E; Reis-Filho JS; Wen HY
    Histopathology; 2019 Jul; 75(1):139-145. PubMed ID: 30843622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.
    Pareja F; Vahdatinia M; Marchio C; Lee SSK; Da Cruz Paula A; Derakhshan F; da Silva EM; Selenica P; Dopeso H; Chandarlapaty S; Wen HY; Vincent-Salomon A; Brogi E; Weigelt B; Reis-Filho JS
    J Clin Pathol; 2022 Jan; 75(1):10-17. PubMed ID: 33148628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.
    Lacroix-Triki M; Suarez PH; MacKay A; Lambros MB; Natrajan R; Savage K; Geyer FC; Weigelt B; Ashworth A; Reis-Filho JS
    J Pathol; 2010 Nov; 222(3):282-98. PubMed ID: 20815046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer.
    Nguyen B; Veys I; Leduc S; Bareche Y; Majjaj S; Brown DN; Boeckx B; Lambrechts D; Sotiriou C; Larsimont D; Desmedt C
    J Natl Cancer Inst; 2019 Jul; 111(7):742-746. PubMed ID: 30789657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Genomic Landscape of Male Breast Cancers.
    Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS
    Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.
    Kyker-Snowman K; Erlanger Avigdor B; Nasim M; Cimino-Mathews A; Wheelan SJ; Argani P; Park BH
    Breast Cancer Res Treat; 2018 Jul; 170(2):425-430. PubMed ID: 29541976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.
    Sun P; Zhong Z; Lu Q; Li M; Chao X; Chen D; Hu W; Luo R; He J
    Mod Pathol; 2020 Oct; 33(10):1945-1960. PubMed ID: 32358590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
    Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A microscopic landscape of the invasive breast cancer genome.
    Ping Z; Xia Y; Shen T; Parekh V; Siegal GP; Eltoum IE; He J; Chen D; Deng M; Xi R; Shen D
    Sci Rep; 2016 Jun; 6():27545. PubMed ID: 27283966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.